Tango Therapeutics, Inc. (NASDAQ:TNGX) Director Mace Rothenberg Acquires 10,000 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) Director Mace Rothenberg purchased 10,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was bought at an average price of $3.62 per share, for a total transaction of $36,200.00. Following the purchase, the director now owns 21,250 shares in the company, valued at approximately $76,925. This represents a 88.89 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mace Rothenberg also recently made the following trade(s):

• On Monday, November 18th, Mace Rothenberg purchased 10,000 shares of Tango Therapeutics stock. The shares were purchased at an average cost of $3.78 per share, with a total value of $37,800.00.

Tango Therapeutics Stock Performance

Tango Therapeutics stock opened at $4.08 on Thursday. The company has a market capitalization of $438.27 million, a PE ratio of -3.26 and a beta of 0.88. The company has a 50 day moving average price of $6.43 and a 200-day moving average price of $8.09. Tango Therapeutics, Inc. has a fifty-two week low of $2.70 and a fifty-two week high of $13.01.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. purchased a new stake in Tango Therapeutics in the second quarter worth about $3,836,000. Vanguard Group Inc. boosted its holdings in shares of Tango Therapeutics by 3.4% in the 1st quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock valued at $24,462,000 after buying an additional 101,673 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Tango Therapeutics by 32.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock worth $230,000 after buying an additional 7,128 shares during the last quarter. Quarry LP bought a new position in shares of Tango Therapeutics during the 2nd quarter worth approximately $99,000. Finally, Point72 DIFC Ltd purchased a new stake in Tango Therapeutics during the second quarter valued at approximately $54,000. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. B. Riley reduced their price target on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Guggenheim cut their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Wedbush lifted their price target on shares of Tango Therapeutics from $11.00 to $13.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research report on Friday, November 8th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tango Therapeutics presently has an average rating of “Buy” and a consensus price target of $13.14.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.